Transplant Genomics announces launch of Trugraf® Liver, the first and only non-invasive gene expression diagnostic test to optimise immunosuppression in liver transplant recipients

Novel diagnostic test utilises gene expression biomarkers to confirm immune quiescence and rule out organ rejection

30 September 2022

Transplant Genomics ("TGI"), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide which is part of the Eurofins network of companies, is pleased to announce the commercial availability of TruGraf® Liver, a blood-based gene expression test that provides guidance for optimisation of immunosuppression therapy in liver transplant recipients. For liver transplant recipients, TruGraf® Liver represents the first diagnostic tool that leverages gene expression data—powered by TGI's proprietary technology and machine learning—to give the earliest and most accurate view of immune quiescence.

Immunosuppressive medication is essential to help prevent organ rejection following liver transplantation. Due to the significant complications associated with the use of immunosuppression, clinicians can choose to reduce immunosuppression for liver transplant recipients to minimise these complications. Until now, immunosuppression optimisation has largely been a "trial and error" process, with clinicians relying only on laboratory and clinical indicators of rejection and graft injury, resulting from the effects of immune activation.

TruGraf® Liver is the first and only blood-based test that offers biomarker guidance to aid physicians in optimising immunosuppression in transplant recipients, to allow for a superior balance between graft rejection and adverse events. TruGraf® Liver can help clinicians confirm immune quiescence during immunosuppression optimisation in patients with stable graft function, minimising the risk of overt graft injury due to rejection.

Josh Levitsky, MD, MS, Professor of Medicine and Surgery in the Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, detailed the development of TruGraf® Liver in his May 2022 article in *Transplantation* (https://pubmed.ncbi.nlm.nih.gov/34342962). This study is based on findings from an NIH-funded, multi-center longitudinal study (CTOT-14: NCT01672164) that has set the stage for the use of non-invasive biomarkers for serial monitoring of liver transplant recipients.

Hepatologists and other liver transplant care professionals may learn more about TruGraf® Liver at www.transplantgenomics.com/trugraf-liver.

For further information:

Investor Relations

Eurofins Scientific SE

Phone: +32 2 766 1620

ir@eurofins.com

About Transplant Genomics, Inc.

Transplant Genomics, Inc. ("TGI") is a personalised diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimisation of therapy. Working alongside the transplant community and within the Eurofins family, TGI is commercialising a suite of tests enabling diagnoses and prediction of transplant recipient immune status. TGI was acquired by the Eurofins Group in 2019.

Learn more about Transplant Genomics at http://www.transplantgenomics.com.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.